Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses

BACKGROUND: High-dose short-term methylprednisolone is the recommended treatment in the management of multiple sclerosis relapses, although it has been suggested that lower doses may be equally effective. Also, glucocorticoids are associated with multiple and often dose-dependent adverse effects. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Caster, Ola, Edwards, I. Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609048/
https://www.ncbi.nlm.nih.gov/pubmed/26475456
http://dx.doi.org/10.1186/s12883-015-0450-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609048/
https://www.ncbi.nlm.nih.gov/pubmed/26475456
http://dx.doi.org/10.1186/s12883-015-0450-x

Ejemplares similares